Compare ADMA Biologics Inc (ADMA) vs Impinj Inc (PI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Impinj Inc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Impinj Inc trades at $142.9 (market cap $4.20B). The key difference: Impinj Inc is the larger of the two by market cap, and Impinj Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | PI | |
|---|---|---|
Market Cap | $2.13B | $4.20B |
Sector | Health | Technology |
52-Week High | $20.38 | $241.91 |
52-Week Low | $7.60 | $91.34 |
Enterprise Value | $2.20B | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Impinj (PI) trades at $148.00, up 4.53% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $167.50. Recent Q1 2026 earnings beat expectations, but the company shows negative net income margins and elevated valuation multiples. Key news includes upcoming Q2 2026 results and insider selling activity.
The stock offers upside potential from strong analyst buy ratings and RFID technology leadership, but risks include persistent profitability challenges, high debt-to-asset ratio (51.52% in 2025), and sensitivity to earnings misses. Investor sentiment is mixed amid growth execution concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
